| 生物活性 |
Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent that increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt, and NF-κB pathways, attenuates retinal ganglion cell death in a normal-tension glaucoma model, exerts neuroprotective effects in a mouse model of Parkinson's disease, prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats as an S100β protein synthesis inhibitor, downregulates neuroinflammation and astrocyte dysfunction after status epilepticus in young rats, and can be used for research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage, and epilepsy. |
体外研究 (In Vitro) |
Arundic acid (0-100 μM; 3-24 h) 可增强人星形胶质细胞 H4 细胞中 EAAT1/EAAT2 启动子的活性。 Arundic acid (6.25-100 μM; 24 h) 通过 Akt、ERK 和 NF-κB 通路介导人星形胶质细胞 H4 细胞中 EAAT1 启动子活性、mRNA、蛋白水平及谷氨酸摄取功能的上调。 Arundic acid (50 μM; 3-24 h) 可通过降低细胞质中 IκBα 水平并诱导 NF-κB p65 的核转位,在人星形胶质细胞 H4 中激活 NF-κB 通路。 Arundic acid (50 μM; 5 min-24 h) 可在处理后 5 min 内激活 Akt 和 ERK 信号通路。 Arundic acid (50 μM; 24 h) 可通过抑制人星形胶质细胞 H4 中被 Mn 激活的 YY1 表达,缓解 Mn 诱导的 EAAT1 表达抑制。 Arundic acid (100 μM; 14 days) 可通过提高 Vmax、不改变谷氨酸亲和力的方式,增强原代培养小鼠 Müller 细胞的谷氨酸摄取速率。 Arundic acid (0-100 μM; 14 days) 可上调原代培养小鼠 Müller 细胞中 GLAST mRNA 的表达。 Arundic acid 可调节培养大鼠大脑星形胶质细胞中的多种星形胶质细胞活化反应,包括抑制 S-100β 上调及促炎基因表达,且不会改变 GFAP 水平。
Real Time qPCR
| Cell Line: |
Primary cultured mouse Müller cells |
| Concentration: |
0, 12.5, 25, 50, 100 μM |
| Incubation Time: |
14 days |
| Result: |
Increased endogenous GLAST mRNA expression. Detected GLAST mRNA induction as early as 24 h post-treatment. |
Western Blot Analysis
| Cell Line: |
human astrocyte H4 cell
|
| Concentration: |
0, 6.25, 12.5, 25, 50, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Increased EAAT1 protein expression. |
Western Blot Analysis
| Cell Line: |
human astrocyte H4 cell |
| Concentration: |
50 μM |
| Incubation Time: |
0, 6, 12, 24 h |
| Result: |
Enhanced NF-κB reporter gene activity and reduced IκBα levels in cytoplasmic components |
|
体内研究 (In Vivo) |
Arundic acid (10 mg/kg; p.o.; daily; 14 days) 可在患有正常眼压性青光眼样变性的 GLAST 杂合子小鼠中上调视网膜 GLAST 表达、增强谷氨酸摄取,并使视网膜神经节细胞计数增加约 19.7%。 Arundic acid (30 mg/kg; i.p.; 5 post-MPTP doses) 在 MPTP (MS-O89430) 帕金森病小鼠模型中可保护小鼠多巴胺能神经元免受 MPTP 的神经毒性作用,维持纹状体 52%的多巴胺水平、黑质 44%的多巴胺能神经元,并改善运动功能缺陷。 Arundic acid (0.02-20 μg/μL; i.c.v.; single dose) 可降低健康雄性 Wistar 大鼠纹状体中的 S100B 和 GFAP 水平。 Arundic acid (2 μg/μL; i.c.v.; single dose;) 可逆转雄性 Wistar 大鼠中 ICH 诱导的神经功能缺损,减小纹状体损伤体积,抑制反应性星形胶质细胞增生,阻止神经元凋亡,使中枢和外周 S100B 水平恢复正常,并增强早期抗氧化防御能力。 Arundic acid (10 mg/kg; i.p.; single injection; 6 h or 24 h post-SE induction) 可通过减轻海马神经炎症、逆转星形胶质细胞功能障碍、恢复谷氨酸稳态并改善葡萄糖摄取,对锂-匹鲁卡品诱导癫痫持续状态 (SE) 的大鼠发挥神经保护作用,其中 SE 诱导后 24 h 给药在各终点指标上显示出更稳定的疗效。
| Animal Model: |
C57BL/6J (backcrossed for ≥10 generations; GLAST heterozygous; postnatal day 22 to 35) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; daily; 14 days |
| Result: |
Increased retinal GLAST mRNA levels relative to vehicle controls. Increased retinal GLAST protein expression relative to vehicle controls. Increased retinal glutamate uptake velocity by 1.23-fold relative to vehicle-treated GLAST+/- mice. Increased GCL neuron count to 438 cells per retina, compared with 366 cells in vehicle-treated GLAST+/- mice. Showed no effect on glutamate uptake in GLAST-/- mice. |
| Animal Model: |
C57BL/6 (male, 10 weeks old, 22-28 g, MPTP-induced Parkinson’s disease) |
| Dosage: |
30 mg/kg |
| Administration: |
i.p.; 5 doses at 1 minute, 6 h, 24 h, 48 h, 72 h after last MPTP injection |
| Result: |
Preserved striatal dopamine levels at 52% of normal control values. Preserved striatal DOPAC and HVA levels at 47% and 60% of normal control values, respectively. Significantly reduced motor function deficits in the pole test (T-turn and T-LA) and catalepsy test. Preserved the number of tyrosine hydroxylase-positive dopaminergic neurons in the substantia nigra pars compacta at 42% of normal control values 3 days after MPTP injection and 44% of normal control values 7 days after MPTP injection. Induced earlier appearance of GFAP-positive reactive astrocytes (by 3 days post-MPTP) compared to MPTP-only mice, with GFAP immunoreactivity comparable to MPTP-only mice at 7 days. Reduced S-100 immunoreactivity in the substantia nigra at 3 days and in the striatum at 7 days post-MPTP compared to MPTP-only mice. Showed no significant effect on microglial activation relative to MPTP-only mice. |
| Animal Model: |
Wistar rats (adult male, 90 days-old, 300-350 g) |
| Dosage: |
0.02 μg/μL; 0.2 μg/μL; 2 μg/μL; 20 μg/μL |
| Administration: |
i.c.v.; single dose |
| Result: |
Significantly reduced striatal S100B immunocontent at 0.2 μg/μL and 2 μg/μL doses compared to control groups. Significantly reduced striatal GFAP immunocontent at 2 μg/μL dose compared to control groups. Showed no inhibitory effect on either S100B or GFAP levels at 20 μg/μL dose. |
| Animal Model: |
Wistar rats (adult male, 90 days-old, 300-350 g, intracerebral hemorrhage induced by intrastriatal injection of type-IV collagenase) |
| Dosage: |
2 μg/μL |
| Administration: |
i.c.v.; single dose; administered immediately before ICH induction |
| Result: |
Reversed motor dysfunction completely at 7 days post-injury, with neurological scores and significantly. Reduced striatal lesion volume significantly at 7 days post-injury. Lowered striatal GFAP and S100B fluorescence intensity and immunostained surface area significantly at 7 days post-injury. Increased NeuN fluorescence intensity and number of NeuN-positive cells significantly at 7 days post-injury. Decreased cleaved caspase-3 fluorescence intensity and number of cleaved caspase-3-positive cells significantly at 7 days post-injury. Lowered striatal GFAP levels significantly at 7 days post-injury. Lowered striatal S100B levels significantly at 7 days post-injury; lowered cerebrospinal fluid S100B levels significantly at 72 hours post-injury; lowered serum S100B levels significantly at 24 hours and 7 days post-injury. Increased striatal GSH levels significantly at 24 hours post-injury. Decreased striatal GS activity significantly at 24 hours post-injury. |
| Animal Model: |
Wistar rats (male, postnatal day 27) |
| Dosage: |
10 mg/kg (6 h post-SE induction); 10 mg/kg (24 h post-SE induction) |
| Administration: |
i.p.; single injection |
| Result: |
Partially reversed elevated hippocampal IL-1β levels, abolished elevated hippocampal TLR4 protein expression, partially reversed elevated hippocampal COX2 protein expression, increased hippocampal TGF-β levels, and did not alter TNF-α, RAGE, or Iba1 levels at 6 h post-SE. Prevented elevated hippocampal IL-1β levels, decreased hippocampal TNF-α levels, prevented elevated hippocampal RAGE and TLR4 protein expression, completely abolished elevated hippocampal COX2 protein expression, partially reversed elevated hippocampal Iba1 levels, and increased hippocampal TGF-β levels at 24 h post-SE. Prevented elevated hippocampal GFAP levels at 6 h and 24 h post-SE. Partially reversed elevated hippocampal S100B levels, reversed reduced hippocampal connexin-43 (Cx-43) protein expression, partially reversed elevated CSF S100B levels, and partially reversed reduced serum S100B levels at 6 h post-SE. Abolished elevated hippocampal S100B levels, and did not alter reduced hippocampal Cx-43 levels or CSF/serum S100B levels at 24 h post-SE. Reversed reduced hippocampal GLAST protein expression, partially reversed reduced hippocampal GLT1 protein expression, reversed increased hippocampal glutamate uptake, did not alter reduced hippocampal GSH levels, partially reversed reduced hippocampal glutamine synthetase (GS) activity, and reversed reduced hippocampal GS protein expression at 6 h post-SE. Partially reversed reduced hippocampal GLAST protein expression, partially reversed reduced hippocampal GLT1 protein expression, reversed increased hippocampal glutamate uptake, prevented reduced hippocampal GSH levels, did not alter reduced hippocampal GS activity, and reversed reduced hippocampal GS protein expression at 24 h post-SE. Abolished reduced hippocampal glucose uptake, and did not alter hippocampal GLUT1 protein expression at 6 h and 24 h post-SE. |
|